Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
- Published in:
- 2021
- By:
- Publication type:
- Report
Works in mAbs, 2021, Vol 13, Issue 1
Results: 102
1
2
Agonistic nanobodies and antibodies to human VISTA.
- Published in:
- 2021
- By:
- Publication type:
- Report
3
Development of a robust and semi-automated two-step antibody purification process.
- Published in:
- 2021
- By:
- Publication type:
- Report
4
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1999195
- By:
- Publication type:
- Article
5
Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX.
- Published in:
- 2021
- By:
- Publication type:
- Report
6
Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX.
- Published in:
- 2021
- By:
- Publication type:
- Report
7
Current strategies for detecting functional convergence across B-cell receptor repertoires.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1996732
- By:
- Publication type:
- Article
8
The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1995929
- By:
- Publication type:
- Article
9
Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies.
- Published in:
- 2021
- By:
- Publication type:
- Report
10
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies.
- Published in:
- 2021
- By:
- Publication type:
- Report
11
Impact of IgG subclass on molecular properties of monoclonal antibodies.
- Published in:
- 2021
- By:
- Publication type:
- Report
12
An efficient system for bioconjugation based on a widely applicable engineered O-glycosylation tag: Short title: Controlled bioconjugation via O-glycan engineering.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1992068
- By:
- Publication type:
- Article
13
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1991552
- By:
- Publication type:
- Article
14
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
- Published in:
- 2021
- By:
- Publication type:
- Report
15
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
- Published in:
- 2021
- By:
- Publication type:
- Report
16
Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1987180
- By:
- Publication type:
- Article
17
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1982447
- By:
- Publication type:
- Article
18
Identification of a CE-SDS shoulder peak as disulfide-linked fragments from common C<sub>H</sub>2 cleavages in IgGs and IgG-like bispecific antibodies.
- Published in:
- 2021
- By:
- Publication type:
- Report
19
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics.
- Published in:
- 2021
- By:
- Publication type:
- Report
20
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer.
- Published in:
- 2021
- By:
- Publication type:
- Report
21
Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry.
- Published in:
- 2021
- By:
- Publication type:
- Report
22
Antibody mix-and-read assays based on fluorescence intensity probes.
- Published in:
- 2021
- By:
- Publication type:
- Report
23
Antibody blockade of CD96 by distinct molecular mechanisms.
- Published in:
- 2021
- By:
- Publication type:
- Report
24
Quantification of natural abundance NMR data differentiates the solution behavior of monoclonal antibodies and their fragments.
- Published in:
- 2021
- By:
- Publication type:
- Report
25
Enhancing the multi-attribute method through an automated and high-throughput sample preparation.
- Published in:
- 2021
- By:
- Publication type:
- Report
26
Versatile and rapid microfluidics-assisted antibody discovery.
- Published in:
- 2021
- By:
- Publication type:
- Report
27
Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET.
- Published in:
- 2021
- By:
- Publication type:
- Report
28
Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate.
- Published in:
- 2021
- By:
- Publication type:
- Report
29
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1967714
- By:
- Publication type:
- Article
30
Correction.
- Published in:
- 2021
- Publication type:
- Correction Notice
31
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1964935
- By:
- Publication type:
- Article
32
A non-clinical comparative study of IL-23 antibodies in psoriasis.
- Published in:
- 2021
- By:
- Publication type:
- Report
33
Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies.
- Published in:
- 2021
- By:
- Publication type:
- Report
34
Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction.
- Published in:
- 2021
- By:
- Publication type:
- Report
35
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.
- Published in:
- 2021
- By:
- Publication type:
- Report
36
Host cell protein detection gap risk mitigation: quantitative IAC-MS for ELISA antibody reagent coverage determination.
- Published in:
- 2021
- By:
- Publication type:
- Report
37
Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
- Published in:
- 2021
- By:
- Publication type:
- Report
38
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development.
- Published in:
- 2021
- By:
- Publication type:
- Report
39
Accurate determination of epitope for antibodies with unknown 3D structures.
- Published in:
- 2021
- By:
- Publication type:
- Report
40
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.
- Published in:
- 2021
- By:
- Publication type:
- Report
41
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.
- Published in:
- 2021
- By:
- Publication type:
- Report
42
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
- Published in:
- 2021
- By:
- Publication type:
- Report
43
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
- Published in:
- 2021
- By:
- Publication type:
- Report
44
The therapeutic potential of sialylated Fc domains of human IgG.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1953220
- By:
- Publication type:
- Article
45
Targeting cancer with antibody-drug conjugates: Promises and challenges.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1951427
- By:
- Publication type:
- Article
46
Highly sensitive detection of antibody nonspecific interactions using flow cytometry.
- Published in:
- 2021
- By:
- Publication type:
- Report
47
Animal- versus in vitro-derived antibodies: avoiding the extremes.
- Published in:
- mAbs (1942-0862), 2021, v. 13, n. 1, p. 1, doi. 10.1080/19420862.2021.1950265
- By:
- Publication type:
- Article
48
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
- Published in:
- 2021
- By:
- Publication type:
- Report
49
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.
- Published in:
- 2021
- By:
- Publication type:
- Report
50
An integrated approach for characterizing immunogenic responses toward a bispecific antibody.
- Published in:
- 2021
- By:
- Publication type:
- Report